Follicular lymphoma: watch and wait is watch and worry

Fredrick B. Hagemeister, ‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas BioDrugs. ,vol. 26, pp. 363- 376 ,(2012) , 10.1007/BF03261894

Giovanni Martinelli, Shu-Fang Hsu Schmitz, Urs Utiger, Thomas Cerny, Urs Hess, Simona Bassi, Emmie Okkinga, Roger Stupp, Rolf Stahel, Marc Heizmann, Daniel Vorobiof, Andreas Lohri, Pierre-Yves Dietrich, Emanuele Zucca, Michele Ghielmini, Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98 Journal of Clinical Oncology. ,vol. 28, pp. 4480- 4484 ,(2010) , 10.1200/JCO.2010.28.4786

David C Linch, Kirit M Ardeshna, Wendi Qian, Paul Smith, Nivette Braganca, Lisa Lowry, Pip Patrick, June Warden, Lindsey Stevens, Christopher F E Pocock, Fiona Miall, David Cunningham, John Davies, Andrew Jack, Richard Stephens, Jan Walewski, Burhan Ferhanoglu, Ken Bradstock, Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology. ,vol. 15, pp. 424- 435 ,(2014) , 10.1016/S1470-2045(14)70027-0

Philippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, Emanuela Anna Pesce, Stefano Pileri, Peter McLaughlin, Stefano Luminari, Barbara Pro, Silvia Montoto, Andrés JM Ferreri, Eric Deconinck, Noël Milpied, Leo I Gordon, Massimo Federico, None, Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database Journal of Clinical Oncology. ,vol. 30, pp. 3848- 3853 ,(2012) , 10.1200/JCO.2010.33.4474

Brad Kahl, Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? Hematology. ,vol. 2012, pp. 433- 438 ,(2012) , 10.1182/ASHEDUCATION-2012.1.433

Lisa Lowry, Kirit M. Ardeshna, Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma? Cancer Journal. ,vol. 18, pp. 390- 395 ,(2012) , 10.1097/PPO.0B013E31826AED4F

Fredrick B. Hagemeister, 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy? BioDrugs. ,vol. 26, pp. 363- 376 ,(2012) , 10.2165/11634320-000000000-00000

Brad S. Kahl, Fangxin Hong, Michael E Williams, Randy D. Gascoyne, Lynne I Wagner, John C. Krauss, Sandra J. Horning, Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma Blood. ,vol. 118, ,(2011) , 10.1182/BLOOD.V118.21.LBA-6.LBA-6

Brad Kahl, Is there a role for “watch and wait” in follicular lymphoma in the rituximab era? Hematology. ,vol. 2012, pp. 433- 438 ,(2012) , 10.1182/ASHEDUCATION.V2012.1.433.3798541